Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva reported Q2 2026 revenue of $119.6 million, up 19% year-over-year, with Innoviva Specialty Therapeutics (IST) net product sales surging 46% to $51.8 million driven by strong U.S. momentum. The company remains on track to achieve at least $150 million in IST U.S. net product sales for 2026 and expanded its reach through a new licensing agreement with Dr.
Key figures
- Revenue
- 119591000
- Revenue Yoy
- 19%
- Cash
- 570400000
- Ist us sales
- 36600000
- Royalty revenue
- 59800000
- Operating income
- 50900000
- Net product sales
- 51800000
- Repurchase amount
- 31400000
- Shares repurchased
- 1403247
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.